生物制剂治疗炎症性肠病成本效益系统综述数据集

数据集获取（Figshare）

• 源站标题：A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases
• DOI：10.1371/journal.pone.0145087
• 发布日期：2015-12-18
• 文件数：5 个
• 文件总体积：535.04 KB
• 源站页面：https://plos.figshare.com/articles/dataset/_A_Systematic_Review_of_the_Cost_Effectiveness_of_Biologics_for_the_Treatment_of_Inflammatory_Bowel_Diseases_/1626021

命令行下载

curl -L -o "S1_File.doc" "https://ndownloader.figshare.com/files/2610296"
curl -L -o "S2_File.doc" "https://ndownloader.figshare.com/files/2610298"
curl -L -o "S1_Table.doc" "https://ndownloader.figshare.com/files/2610299"
curl -L -o "S2_Table.doc" "https://ndownloader.figshare.com/files/2610301"
curl -L -o "S3_Table.doc" "https://ndownloader.figshare.com/files/2610302"

文件清单

• S1_File.doc（26.11 KB）
• S2_File.doc（32.26 KB）
• S1_Table.doc（34.82 KB）
• S2_Table.doc（349.70 KB）
• S3_Table.doc（92.16 KB）

文件总体积 535.04 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background
Biologics are used for the treatment of inflammatory bowel diseases, Crohn´s disease and ulcerative colitis refractory to conventional treatment. In order to allocate healthcare spending efficiently, costly biologics for inflammatory bowel diseases are an important target for cost-effectiveness analyses. The aim of this study was to systemically review all published literature on the cost-effectiveness of biologics for inflammatory bowel diseases and to evaluate the methodological quality of cost-effectiveness analyses.
Methods
A literature search was performed using Medline (Ovid), Cochrane Library, and SCOPUS. All cost-utility analyses comparing biologics with conventional medical treatment, another biologic treatment, placebo, or surgery for the treatment of inflammatory bowel diseases in adults were included in this review. All costs were converted to the 2014 euro. The methodological quality of the included studies was assessed by Drummond’s, Philips’, and the Consolidated Health Economic Evaluation Reporting Standards checklist.
Results
Altogether, 25 studies were included in the review. Among the patients refractory to conventional medical treatment, the incremental cost-effectiveness ratio ranged from dominance to 549,335 €/Quality-Adjusted Life Year compared to the incremental cost-effectiveness ratio associated with conventional medical treatment. When comparing biologics with another biologic treatment, the incremental cost-effectiveness ratio ranged from dominance to 24,012,483 €/Quality-Adjusted Life Year. A study including both direct and indirect costs produced more favorable incremental cost-effectiveness ratios than those produced by studies including only direct costs.
Conclusions
With a threshold of 35,000 €/Quality-Adjusted Life Year, biologics seem to be cost-effective for the induction treatment of active and severe inflammatory bowel disease. Between biologics, the cost-effectiveness remains unclear.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0145087（source: https://plos.figshare.com/articles/dataset/_A_Systematic_Review_of_the_Cost_Effectiveness_of_Biologics_for_the_Treatment_of_Inflammatory_Bowel_Diseases_/1626021）。